Search research articles
Contact Us
Filters
Showing results (271-280 of 596) with videos related to
Page
of 60
Sort By:
Cell Reports
|
February 2, 2018
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Agnieszka K Witkiewicz, Sejin Chung, Rachel Brough, et al.
The Oncologist
|
July 24, 2025
Under the radar-frequency, timing, duration and trajectory of lower grade adverse events in clinical trials of anti-cancer therapies
Katherine E Francis, Sarah J Lord, Sandy Simon, et al.
The Australian and New Zealand Journal of Surgery
|
March 1, 1988
Experience with the Nesbit procedure in the treatment of penile curvature
G R Watters, Z S Wisniewski, C M Earle, et al.
Thrombosis and Haemostasis
|
October 7, 2009
Is perioperative point-of-care prothrombin time testing accurate compared to the standard laboratory test?
Natalie Urwyler, Lukas P Staub, Dominik Beran, et al.
British Journal of Cancer
|
March 15, 2012
Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis
H Verry, S J Lord, A Martin, et al.
Therapeutic Advances in Medical Oncology
|
August 11, 2018
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
Katrin M Sjoquist, Sarah J Lord, Michael L Friedlander, et al.
Biochemical and Biophysical Research Communications
|
May 24, 1996
The polyether bistratene A activates protein kinase C-delta and induces growth arrest in HL60 cells
G Griffiths, B Garrone, E Deacon, et al.
Paraplegia
|
April 1, 1992
The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury
C M Earle, E J Keogh, J K Ker, et al.
Southern Medical Journal
|
April 1, 1993
The Texas Breast Screening Project: Part I. Mammographic and clinical results
G N Peters, V G Vogel, W P Evans, et al.
EMBO Molecular Medicine
|
January 6, 2010
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
Sarah A Martin, Afshan McCarthy, Louise J Barber, et al.
Page
of 60
Search research articles
Search
Showing results (271-280 of 596) with videos related to
Sort By:
Page
of 60
Cell Reports
|
February 2, 2018
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Agnieszka K Witkiewicz, Sejin Chung, Rachel Brough, et al.
The Oncologist
|
July 24, 2025
Under the radar-frequency, timing, duration and trajectory of lower grade adverse events in clinical trials of anti-cancer therapies
Katherine E Francis, Sarah J Lord, Sandy Simon, et al.
The Australian and New Zealand Journal of Surgery
|
March 1, 1988
Experience with the Nesbit procedure in the treatment of penile curvature
G R Watters, Z S Wisniewski, C M Earle, et al.
Thrombosis and Haemostasis
|
October 7, 2009
Is perioperative point-of-care prothrombin time testing accurate compared to the standard laboratory test?
Natalie Urwyler, Lukas P Staub, Dominik Beran, et al.
British Journal of Cancer
|
March 15, 2012
Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis
H Verry, S J Lord, A Martin, et al.
Therapeutic Advances in Medical Oncology
|
August 11, 2018
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
Katrin M Sjoquist, Sarah J Lord, Michael L Friedlander, et al.
Biochemical and Biophysical Research Communications
|
May 24, 1996
The polyether bistratene A activates protein kinase C-delta and induces growth arrest in HL60 cells
G Griffiths, B Garrone, E Deacon, et al.
Paraplegia
|
April 1, 1992
The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury
C M Earle, E J Keogh, J K Ker, et al.
Southern Medical Journal
|
April 1, 1993
The Texas Breast Screening Project: Part I. Mammographic and clinical results
G N Peters, V G Vogel, W P Evans, et al.
EMBO Molecular Medicine
|
January 6, 2010
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
Sarah A Martin, Afshan McCarthy, Louise J Barber, et al.
Page
of 60